Insulet (PODD) Stock Price, News & Analysis

Company Overview

Insulet Corporation is a medical device company specializing in the design, development and manufacture of tubeless insulin delivery systems. With a focus on simplifying diabetes management, Insulet markets its flagship Omnipod product line, which includes wearable, disposable insulin pods and accompanying handheld controllers. The company’s mission centers on improving the lives of people with insulin-dependent diabetes through user-friendly, technology-driven solutions.

The Omnipod System consists of a small, waterproof pod that adheres directly to the skin and delivers continuous subcutaneous insulin via preset dosing, along with a personal diabetes manager (PDM) that wirelessly programs and monitors insulin delivery. Insulet has expanded its product portfolio to include the Omnipod DASH® Insulin Management System and the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitoring (CGM) sensors to adjust insulin dosing in real time. The company also provides mobile applications and cloud‐based platforms to support data sharing and remote patient monitoring.

Founded in 2000 and headquartered in Acton, Massachusetts, Insulet went public in 2007 and has since grown into a global organization serving customers across North America, Europe, Australia, Japan and other international markets. Insulet oversees its own manufacturing facilities and collaborates with third‐party partners to ensure a consistent supply of high-quality pods and electronic components. The company invests heavily in research and development to drive next-generation features, enhance user experience and expand indications for its technology.

Under the leadership of President and Chief Executive Officer John Freda, Insulet emphasizes a patient-centric culture and strategic expansion into new geographies and clinical applications. The management team combines expertise in medical technology, regulatory affairs and commercial operations to guide the company’s long-term growth. Through continuous innovation and a commitment to simplifying insulin delivery, Insulet aims to set new standards in diabetes care and support better outcomes for people living with diabetes.

Key Stats

• Today's Range: $295.18 to $302.48
• 50-Day Range: $250.25 to $327.47
• 52-Week Range: $173.00 to $329.33
• Volume: 711,837 shs
• Average Volume: 720,211 shs
• Market Capitalization: $20.87 billion
• P/E Ratio: 53.33
• Dividend Yield: N/A
• Price Target: $321.00
• Consensus Rating: Moderate Buy

Insulet Stock Analysis - MarketRank™

Insulet scored higher than 82% of companies evaluated by MarketBeat, and ranked 167th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Insulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Insulet has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 26.79%

Earnings Growth

Earnings for Insulet are expected to grow by 26.79% in the coming year, from $3.92 to $4.97 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Insulet is 53.65, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of Insulet is 53.65, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.02.

Price to Earnings Growth Ratio

Insulet has a PEG Ratio of 2.69. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Insulet has a P/B Ratio of 17.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.72% of the float of Insulet has been sold short.

Short Interest Ratio / Days to Cover

Insulet has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insulet has recently increased by 0.53%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Insulet does not currently pay a dividend.

Dividend Growth

Insulet does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.9 / 5
• Environmental Score: -1.20

Percentage of Shares Shorted

2.72% of the float of Insulet has been sold short.

Short Interest Ratio / Days to Cover

Insulet has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insulet has recently increased by 0.53%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.83

News Sentiment

Insulet has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Insulet this week, compared to 14 articles on an average week.

Search Interest

Only 8 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,680,885.00 in company stock.

Percentage Held by Insiders

Only 0.39% of the stock of Insulet is held by insiders.

PODD Stock Analysis - Frequently Asked Questions

How have PODD shares performed this year?

Insulet's stock was trading at $261.07 at the beginning of 2025. Since then, PODD shares have increased by 14.3% and is now trading at $298.32.

How were Insulet's earnings last quarter?

Insulet Corporation (NASDAQ:PODD) announced its quarterly earnings data on Thursday, May, 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet's revenue was up 28.8% compared to the same quarter last year.
Read the conference call transcript.

Who are Insulet's major shareholders?

Top institutional shareholders of Insulet include Gradient Investments LLC (0.08%), Paladin Wealth LLC, Parallel Advisors LLC and Kera Capital Partners Inc.. Insiders that own company stock include Charles Alpuche, Timothy J Scannell, James Hollingshead, John W Kapples, Wayde D Mcmillan, Bret Christensen, Mark N Field, Eric Benjamin, Michael P Spears, Lauren Budden, Dan Manea, Prem Singh, Wayne AI Frederick, Shacey Petrovic and Luciana Borio.
View institutional ownership trends.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Bank of America (BAC), Wayfair (W) and Wells Fargo & Company (WFC).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:PODD
• CIK: 1145197
• Web: www.insulet.com
• Phone: (978) 600-7000
• Fax: 978-600-0120
• Employees: 3,900
• Year Founded: 2000

Price Target and Rating

• Average Stock Price Target: $321.00
• High Stock Price Target: $380.00
• Low Stock Price Target: $223.00
• Potential Upside/Downside: +6.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.56
• Trailing P/E Ratio: 54.08
• Forward P/E Ratio: 76.71
• P/E Growth: 2.69
• Net Income: $418.30 million
• Net Margins: 18.29%
• Pretax Margin: 13.34%
• Return on Equity: 22.25%
• Return on Assets: 8.29%

Debt

• Debt-to-Equity Ratio: 1.21
• Current Ratio: 4.47
• Quick Ratio: 3.63

Sales & Book Value

• Annual Sales: $2.07 billion
• Price / Sales: 10.22
• Cash Flow: $4.43 per share
• Price / Cash Flow: 67.86
• Book Value: $17.27 per share
• Price / Book: 17.41

Miscellaneous

• Outstanding Shares: 70,380,000
• Free Float: 70,101,000
• Market Cap: $21.16 billion
• Optionable: Optionable
• Beta: 1.35